<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260710070117N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-20</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Oral versus Intramuscular Ketamine for Pediatric Procedural Sedation</public_title>
      <acronym>NIK-PedPSA</acronym>
      <scientific_title>Efficacy of Oral Compared with Intramuscular Ketamine for Analgesia and Procedural Sedation in Pediatric Patients Presenting to the Emergency Department of Imam Khomeini Hospital complex in 2026-2027: A Randomized Non-Inferiority Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-02</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>114</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93250</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be randomized individually in a 1:1:1 allocation ratio to one of the following three groups:

Oral ketamine 10 mg/kg
Oral ketamine 15 mg/kg
Intramuscular ketamine 4 mg/kg
The randomization sequence will be generated by an independent researcher or statistician using statistical software and permuted blocks of varying sizes (4 and 6). No quasi-randomization method will be used, and no stratified randomization will be performed.

Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes containing the randomization assignments. Envelopes will be opened consecutively only after eligibility has been confirmed and written informed consent has been obtained. Outcome assessors and data analysts will remain blinded to treatment allocation.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Pediatric Procedural Sedation and Analgesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Patients in this group receive oral ketamine hydrochloride at a single dose of 10 milligrams per kilogram of body weight (maximum total dose 500 milligrams). The oral formulation is prepared using parenteral ketamine hydrochloride vial (concentration: 50 milligrams per milliliter), which is mixed in a 1 to 1 ratio with a sweet flavored syrup or fruit juice to mask the bitter taste and administered orally using an oral syringe. The child is monitored continuously for vital signs, sedation depth, and oxygen saturation. If adequate procedural sedation is not achieved within 30 minutes, rescue parenteral sedation is provided. Intervention 2: Intervention group 2: Patients in this group receive oral ketamine hydrochloride at a single dose of 15 milligrams per kilogram of body weight (maximum total dose 500 milligrams). The formulation is prepared using parenteral ketamine hydrochloride solution (concentration: 50 milligrams per milliliter) mixed in a 1 to 1 ratio with a sweet flavored syrup to enhance palatability, administered orally via syringe in a single dose. Continuous hemodynamic and sedation depth monitoring is performed. In case of inadequate sedation after 30 minutes, rescue sedation is administered according to protocol. Intervention 3: Control group: Patients in this active comparator control group receive intramuscular ketamine hydrochloride at a single dose of 4 milligrams per kilogram of body weight (maximum total dose 200 milligrams). The injection is administered deep into the vastus lateralis or deltoid muscle using injectable ketamine hydrochloride solution (concentration: 50 milligrams per milliliter). Continuous vital sign monitoring, sedation scoring, and post-procedure recovery evaluations are performed until discharge criteria are met.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
De-identified individual participant dataset containing baseline demographic characteristics, procedural sedation efficacy outcomes based on the Pediatric Sedation State Scale, hemodynamic parameters, sedation and recovery durations, and adverse event profiles; alongside the full study protocol, statistical analysis plan, analytic codes, and data dictionary.

When:
Beginning 6 months following the official publication of the primary trial results in a peer-reviewed scientific journal, and remaining accessible for a duration of 5 years.

To whom:
Qualified academic researchers, clinical investigators, and biostatisticians affiliated with recognized academic or research institutions.

Conditions:
Exclusively for non-commercial, scientifically valid research purposes, systematic reviews, or meta-analyses, governed by an approved study proposal and the execution of a formal data use and confidentiality agreement.

Where to obtain:
Directly obtainable upon formal written request directed to the corresponding author’s institutional email address.

How to obtain:
Interested researchers must submit a formal request comprising a brief research proposal, statistical analysis outline, and institutional ethics approval to the corresponding author. Following methodological review and approval by the principal investigator, a formal Data Use Agreement is signed, and the de-identified data files are securely transferred.

Comments:
All shared data are strictly de-identified with no direct patient identifiers, ensuring that participant privacy and confidentiality are fully protected in compliance with research ethics principles and the International Committee of Medical Journal Editors standards.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Taha Bayat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>emergency department, Imam Khomeini hospital complex, end of Keshavarz Blvd</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>+98 21 6119 0000</telephone>
        <email>t-bayat@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Taha Bayat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emergency Department, Imam Khomeini hospital complex, end of Keshavarz Blvd, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733141</zip>
        <telephone>009821611190000</telephone>
        <email>t-bayat@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pediatric patients aged 1 to 15 years
Clinical indication for procedural sedation and analgesia (PSA) for a therapeutic procedure such as laceration repair
Hemodynamic and vital signs stability prior to intervention
Written informed consent obtained from parents or legal guardians</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>15 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Known hypersensitivity or previous adverse reaction to ketamine
Suspected or confirmed open-globe eye injury
Traumatic brain injury (TBI)
Uncontrolled hypertension
Requirement for a procedure exceeding standard emergency interventions (anticipated procedure duration &gt;30 minutes)
Glasgow Coma Scale (GCS) score &lt; 15
Hemodynamic instability based on the treating physician’s clinical judgment
Administration of any sedative agent within the preceding 24 hours
Known congenital heart disease or active cardiac dysrhythmias
Pre-existing underlying cardiac, respiratory, or neurological diseases
Uncorrected mineralocorticoid deficiency
Known or suspected hepatic failure/dysfunction
Structural airway abnormalities or high risk of airway obstruction
Increased risk of pulmonary aspiration based on fasting status or physician’s discretion
Concomitant use of medications with significant potential for drug interaction with ketamine
Obstructive sleep apnea (OSA)
Known or suspected renal impairment/failure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Patients in this group receive oral ketamine hydrochloride at a single dose of 10 milligrams per kilogram of body weight (maximum total dose 500 milligrams). The oral formulation is prepared using parenteral ketamine hydrochloride vial (concentration: 50 milligrams per milliliter), which is mixed in a 1 to 1 ratio with a sweet flavored syrup or fruit juice to mask the bitter taste and administered orally using an oral syringe. The child is monitored continuously for vital signs, sedation depth, and oxygen saturation. If adequate procedural sedation is not achieved within 30 minutes, rescue parenteral sedation is provided.</i_keyword>
      <i_keyword>Intervention group 2: Patients in this group receive oral ketamine hydrochloride at a single dose of 15 milligrams per kilogram of body weight (maximum total dose 500 milligrams). The formulation is prepared using parenteral ketamine hydrochloride solution (concentration: 50 milligrams per milliliter) mixed in a 1 to 1 ratio with a sweet flavored syrup to enhance palatability, administered orally via syringe in a single dose. Continuous hemodynamic and sedation depth monitoring is performed. In case of inadequate sedation after 30 minutes, rescue sedation is administered according to protocol.</i_keyword>
      <i_keyword>Control group: Patients in this active comparator control group receive intramuscular ketamine hydrochloride at a single dose of 4 milligrams per kilogram of body weight (maximum total dose 200 milligrams). The injection is administered deep into the vastus lateralis or deltoid muscle using injectable ketamine hydrochloride solution (concentration: 50 milligrams per milliliter). Continuous vital sign monitoring, sedation scoring, and post-procedure recovery evaluations are performed until discharge criteria are met.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Proportion of patients with successful procedural sedation (defined as achieving a score of 2 or 3 on the Pediatric Sedation State Scale and successful completion of the procedure without the need for supplemental or rescue sedation). Timepoint: From the time of drug administration until the completion of the procedure (evaluated at 5, 10, 15, 20, 25, and 30 minutes post-administration and immediately upon procedure completion). Method of measurement: Pediatric Sedation State Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Time to sedation onset (the time elapsed in minutes from drug administration until achieving a score of 2 or 3 on the Pediatric Sedation State Scale). Timepoint: From drug administration until achieving target sedation level (continuously monitored during the first 30 minutes). Method of measurement: Digital stopwatch and recording based on the Pediatric Sedation State Scale assessment.</sec_outcome>
      <sec_outcome>Total effective sedation duration (the time elapsed in minutes from the onset of adequate sedation until the patient returns to wakefulness). Timepoint: From the onset of effective sedation until full awakening. Method of measurement: Digital stopwatch and clinical evaluation by the study observer.</sec_outcome>
      <sec_outcome>Time to discharge readiness. Timepoint: During the recovery phase after procedure completion, assessed at 15, 30, 45, 60, 90, and 120 minutes post-procedure. Method of measurement: Pediatric Sedation State Scale assessment.</sec_outcome>
      <sec_outcome>Incidence of acute adverse events including nausea, vomiting, respiratory events, emergence reactions, and hemodynamic instability. Timepoint: From the time of drug administration until final discharge from the emergency department. Method of measurement: Continuous pulse oximetry, non-invasive blood pressure monitoring, clinical observation, and standardized adverse event checklist.</sec_outcome>
      <sec_outcome>Proportion of patients requiring supplemental dosing or rescue sedation due to inadequate sedation after 30 minutes or sedation failure. Timepoint: Within 30 minutes following the initial drug administration. Method of measurement: Clinical Case Report Form and patient medical record.</sec_outcome>
      <sec_outcome>Physician satisfaction with the quality of sedation and procedural ease. Timepoint: Immediately after procedure completion. Method of measurement: 5-point Likert satisfaction scale questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-08-18</approval_date>
        <contact_name>Research Ethics Committees of Imam Khomeini Hospital Complex- Tehran University of Medical Sciences</contact_name>
        <contact_address>Imam Khomeini Hospital Complex, End of Keshavarz Blvd Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
